1. HALTHCC as a novel tumor response metric in patients with hepatocellular carcinoma undergoing locoregional therapy while awaiting liver transplantation. (March 2018) Authors: Sasaki, K.; Firl, D.J.; Kimura, S.; McVey, J.; Fontan, F.; Hashimoto, K.; Yeh, H.; Miller, C.M.; Markmann, J.F.; Aucejo, N.F. Journal: HPB Issue: Volume 20(2018)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Highest overall neutrophil to lymphocyte ratio on waiting list predicts recurrence-free survival in liver transplantation for hepatocellular carcinoma. (March 2018) Authors: Sasaki, K.; Firl, D.J.; Simon, R.; Takahashi, H.; Pitchaimuthu, M.; Kahramangil, B.; Acevedo-Moreno, L.A.; Kose, E.; Nair, A.; Berber, E.; Aucejo, F.N.; McVey, John Journal: HPB Issue: Volume 20(2018)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗